Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

FRAZER, Pa., Feb. 13 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) issued the following statement in response to a complaint filed today by the U.S. Federal Trade Commission (FTC) in U.S. District Court for the District of Columbia challenging the validity of certain agreements entered into by the company in late 2005 and early 2006 to settle the PROVIGIL(R) (modafinil) [C-IV] patent infringement litigation and seeking to permanently enjoin the Company from maintaining or enforcing these agreements.

Cephalon stands by the strength and validity of our PROVIGIL patents and the legal basis for these settlements. We are disappointed that the FTC has determined to challenge these agreements as we believe they fully comply with both the spirit and letter of the antitrust laws. As importantly, our settlements confer a meaningful benefit to U.S. consumers by providing for the entry of generic modafinil three years early.

Cephalon is prepared to vigorously defend itself in this matter and expects to prevail.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL, FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone fo
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... , October 27, 2014 ... to produce, exhibit and sell its artificial "lower ... impeach their patent.      (Photo: ... years of fighting, the definitive judgement has arrived: ... produces innovative and accessible hi-tech prostheses with composite ...
(Date:10/27/2014)... 2014 New Q4-2014 incentives help ... an industry leading unified communication and collaboration provider, ... to deliver cloud-based audio and web/video conferencing solutions ... With SoundConnect’s Q4 incentive partners will ... web conferencing licenses sold, now through December 31st, ...
(Date:10/27/2014)... Janssen Biotech, Inc. and the Crohn,s ... the launch of Get Your Full ... designed to provide resources for people living with ... of nutrition and appropriate therapy in managing IBD. ... with this release, please click: http://www.multivu.com/players/English/7261131-janssen-ccfa-get-your-full-course-for-ibd-wellness-with-sunny-anderson/ ...
(Date:10/25/2014)... 2014 The report “Adipic Acid ... Geography - Global Trends & Forecast to 2019” ... to market drivers, opportunities, and trends in different ... 27 figures spread through 217 slides and in-depth ... & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early ...
Breaking Biology Technology:Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2SoundConnect Unveils Q4 Partner Incentives 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4
... ET, LOS ANGELES, Aug. 31 Signalife, Inc. (Amex:,SGN), Lowell ... update since his matriculation into the Presidency,last month: 1. Dr. ... positions that were producing no revenue whatsoever and no ... Company, in his view. That was done ...
... Aug. 30 Cepheid (Nasdaq:,CPHD) will present at ... the Four Seasons Hotel, Boston, September 5 to ... Senior Vice President, Finance and,Chief Financial Officer, John ... on,September 7. The webcast, along with accompanying ...
... ON, Aug. 30 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated products ... subsidiary, YM BioSciences USA,Inc. ("YM-USA") has been cleared ... initiate a Phase II trial investigating nimotuzumab in ...
Cached Biology Technology:Signalife Provides Corporate Update 2Signalife Provides Corporate Update 3Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 3YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 4YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 5
(Date:10/29/2014)... 2014 — Cambridge, MA and Hebei, China — BGI ... high quality sequencing of the Jujube genome. Jujube is ... and the Jujube genome is particularly difficult to sequence ... factors. It is the first time that a genome ... study has been recently published in Nature ...
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... novel environment are linked to individual differences in ... completed at the University of Eastern Finland and ... study used novel, long-term observations of individual behaviour ... if behaviours predict the vulnerability to fishing in ... rearing environments. Based on the results, it ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3Fish 'personality' linked to vulnerability to angling 2
... is the primary component of nursery container substrates in ... widely used organic material is prompting researchers to investigate ... James E. Altland and Charles Krause of the USDA ... Development Center was designed to determine if ground switchgrass ...
... statistics buried within patient records or detailed in newspaper ... patterns, allowing the discovery of trends that were previously ... use of interactive maps and graphs, combined with word ... events like the spread of Swine flu," said Frank ...
... the Braunschweiger Helmholtz-Zentrums fr Infektionsforschung (Helmholtz Center for ... bacterial communities are able to support the degradation ... collaboration of thirteen partners from nine countries. Research ... today at the HZI. The significance of this ...
Cached Biology News:Switchgrass proves viable as nursery container substrate 2Switchgrass proves viable as nursery container substrate 3Visualization of geographic patterns may predict spread of disease 2Improving the degradation of toxic hydrocarbons 2
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: